Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05786664 · ClinicalTrials.gov registry record
Breast Cancer Survivorship Biorepository
A clinical trial of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by University of Southern California.
- Recruiting
- Registry status
- 1,300
- Enrollment target
- 1
- Study location
NCT05786664 is a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 1,300 participants, above the 289-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (350% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05786664, a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- 1,300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Survey Administration
- OTHER Electronic Health Record Review
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2028-04-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05786664
The ClinicalTrials.gov registry entry for NCT05786664 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 289-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (350% higher). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT05786664 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05786664 about?
NCT05786664 is a clinical study titled "Breast Cancer Survivorship Biorepository". This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer ...
What is the current status of trial NCT05786664?
This trial is currently recruiting. The enrollment target is 1,300 participants. The study started on 2022-04-11. Estimated completion is 2028-04-11.
What conditions does trial NCT05786664 study?
This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Invasive Breast Carcinoma.
What interventions are being tested in trial NCT05786664?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Survey Administration (OTHER), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05786664?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05786664 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anatomic Stage III Breast Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
RECRUITING · NA
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
RECRUITING · NA
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 4
Explore more on PlainTrial
Anatomic Stage III Breast Cancer AJCC v8
All registered trials for this condition
Anatomic Stage II Breast Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.